|
1
|
Zhu X, Ma Y and Liu D: Novel agents and
regiments for acute myeloid leukemia: 2009 ASH annual meeting
highlights. J Hematol Oncol. 3:172010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Estey EH: Acute myeloid leukemia: 2012
update on diagnosis, risk stratification and management. Am J
Hematol. 87:89–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rowe JM and Tallman MS: How I treat acute
myeloid leukemia. Blood. 116:3147–3156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gregory TK, Wald D, Chen Y, Vermaat JM,
Xiong Y and Tse W: Molecular prognostic markers for adult acute
myeloid leukemia with normal cytogenetics. J Hematol Oncol.
2:232009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Juliusson G, Antunovic P, Derolf A,
Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A and
Hoglund M: Age and acute myeloid leukemia: Real world data on
decision to treat and outcomes from the Swedish Acute Leukemia
Registry. Blood. 113:4179–4187. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada K, Furusawa S, Saito K, Waga K,
Koike T, Arimura H, Aoyagi A, Yamato H, Sakuma H, Tsunogake S, et
al: Concurrent use of granulocyte colony-stimulating factor with
low-dose cytosine arabinoside and aclarubicin for previously
treated acute myelogenous leukemia: A pilot study. Leukemia.
9:10–14. 1995.PubMed/NCBI
|
|
7
|
Wei G, Ni W, Chiao JW, Cai Z, Huang H and
Liu D: A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF)
regimen for the treatment of 1029 patients with acute myeloid
leukemia and myelodysplastic syndrome. J Hematol Oncol. 4:462011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Collins RJ, Verschuer LA, Harmon BV,
Prentice RL, Pope JH and Kerr JF: Spontaneous programmed death
(apoptosis) of B-chronic lymphocytic leukaemia cells following
their culture in vitro. Br J Haematol. 71:343–350. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nwajei F and Konopleva M: The bone marrow
microenvironment as niche retreats for hematopoietic and leukemic
stem cells. Adv Hematol. 2013:9539822013.PubMed/NCBI
|
|
10
|
Mèndez-Ferrer S, Michurina TV, Ferraro F,
Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A,
Enikolopov GN and Frenette PS: Mesenchymal and haematopoietic stem
cells form a unique bone marrow niche. Nature. 466:829–834. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caligaris-Cappio F: Role of the
microenvironment in chronic lymphocytic leukaemia. Br J Haematol.
123:380–388. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Azab AK, Runnels JM, Pitsillides C, Moreau
AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, et al:
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple
myeloma cells with the bone marrow microenvironment and enhances
their sensitivity to therapy. Blood. 113:4341–4351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin T and Li L: The stem cell niches in
bone. J Clin Invest. 116:1195–1201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling
X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, et al:
Targeting the leukemia microenvironment by CXCR4 inhibition
overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood. 113:6215–6224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tavor S, Eisenbach M, Jacob-Hirsch J,
Golan T, Petit I, Benzion K, Kay S, Baron S, Amariglio N, Deutsch
V, et al: The CXCR4 antagonist AMD3100 impairs survival of human
AML cells and induces their differentiation. Leukemia.
22:2151–5158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sison EA, Rau RE, McIntyre E, Li L, Small
D and Brown P: MLL-rearranged acute lymphoblastic leukaemia stem
cell interactions with bone marrow stroma promote survival and
therapeutic resistance that can be overcome with CXCR4 antagonism.
Br J Haematol. 160:785–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Busillo JM and Benovic JL: Regulation of
CXCR4 signaling. Biochim Biophys Acta. 1768:952–963. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vianello F, Villanova F, Tisato V, Lymperi
S, Ho KK, Gomes AR, Marin D, Bonnet D, Apperley J, Lam EW and Dazzi
F: Bone marrow mesenchymal stromal cells non-selectively protect
chronic myeloid leukemia cells from imatinib-induced apoptosis via
the CXCR4/CXCL12 axis. Haematologica. 95:1081–1089. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burger JA and Kipps TJ: CXCR4: A key
receptor in the crosstalk between tumor cells and their
microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Y, Stamatoyannopoulos G and Song CZ:
Down-regulation of CXCR4 by inducible small interfering RNA
inhibits breast cancer cell invasion in vitro. Cancer Res.
63:4801–4804. 2003.PubMed/NCBI
|
|
22
|
Labbaye C, Spinello I, Quaranta MT, Pelosi
E, Pasquini L, Petrucci E, Biffoni M, Nuzzolo ER, Billi M, Foà R,
et al: A three-step pathway comprising PLZF/miR-146a/CXCR4 controls
megakaryopoiesis. Nat Cell Biol. 10:788–801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HK, De La Luz Sierra M, Williams CK,
Gulino AV and Tosato G: G-CSF down-regulation of CXCR4 expression
identified as a mechanism for mobilization of myeloid cells. Blood.
108:812–820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
De La Luz Sierra M, Gasperini P,
McCorimick PJ, Zhu J and Tosato G: Transcription factor Gfi-1
induced by G-CSF is a negative regulator of CXCR4 in myeloid cells.
Blood. 110:2276–2285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Donahue RE, Jin P, Bonifacino AC, Metzger
ME, Ren J, Wang E and Stroncek DF: Plerixafor (AMD3100) and
granulocyte colony-stimulating factor (G-CSF) mobilize different
CD34+ cell populations based on global gene and microRNA expression
signatures. Blood. 114:2530–2541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Förster R, Kremmer E, Schubel A, Breitfeld
D, Kleinschmidt A, Nerl C, Bernhardt G and Lipp M: Intracellular
and surface expression of the HIV-1 coreceptor CXCR4/fusin on
various leukocyte subsets: Rapid internalization and recycling upon
activation. J Immunol. 160:1522–1531. 1998.PubMed/NCBI
|
|
28
|
Fernandez HF, Sun Z, Yao X, Litzow MR,
Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP,
Bennett JM, et al: Anthracycline dose intensification in acute
myeloid leukemia. N Engl J Med. 361:1249–1259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bai A, Kojima H, Hori M, Nara N, Komeno T,
Hasegawa Y, Ninomiya H, Abe T and Nagasawa T: Priming with G-CSF
effectively enhances low-dose Ara-C-induced in vivo apoptosis in
myeloid leukemia cells. Exp Hematol. 27:259–265. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tafuri A and Andreeff M: Kinetic rationale
for cytokine-induced recruitment of myeloblastic leukemia followed
by cycle-specific chemotherapy in vitro. Leukemia. 4:826–834.
1990.PubMed/NCBI
|
|
31
|
Ferrero D, Carlesso N, Pregno P, Gallo E
and Pileri A: Self-renewal inhibition of acute myeloid leukemia
clonogenic cells by biological inducers of differentiation.
Leukemia. 6:100–106. 1992.PubMed/NCBI
|
|
32
|
Spinello I, Quaranta MT, Riccioni R, Riti
V, Pasquini L, Boe A, Pelosi E, Vitale A, Foà R, Testa U and
Labbaye C: MicroRNA-146a and AMD3100, two ways to control CXCR4
expression in acute myeloid leukemias. Blood Cancer J. 1:e262011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dalton WT Jr, Ahearn MJ, McCredie KB,
Freireich EJ, Stass SA and Trujillo JM: HL-60 cell line was derived
from a patient with FAB-M2 and not FAB-M3. Blood. 71:242–247.
1988.PubMed/NCBI
|
|
34
|
Hendrix CW, Flexner C, MacFarland RT,
Giandomenico C, Fuchs EJ, Redpath E, Bridger G and Henson GW:
Pharmacokinetics and safety of AMD-3100, a novel antagonist of the
CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents
Chemother. 44:1667–1673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stamatopoulos B, Meuleman N, De Bruyn C,
Pieters K, Mineur P, Le Roy C, Saint-Georges S, Varin-Blank N,
Cymbalista F, Bron D and Lagneaux L: AMD3100 disrupts the
cross-talk between chronic lymphocytic leukemia cells and a
mesenchymal stromal or nurse-like cell-based microenvironment:
Pre-clinical evidence for its association with chronic lymphocytic
leukemia treatments. Haematologica. 97:608–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Campbell JJ, Qin S, Bacon KB, Mackay CR
and Butcher EC: Biology of chemokine and classical chemoattractant
receptors: differential requirements for adhesion-triggering versus
chemotactic responses in lymphoid cells. J Cell Biol. 134:255–266.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Flomenberg N, Devine SM, DiPersio JF,
Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K and Calandra
G: The use of AMD3100 plus G-CSF for autologuos hematopoietic
progentior cell mobilization is superior to G-CSF alone. Blood.
106:1867–1874. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Winkler IG, Pettit AR, Raggatt LJ,
Jacobsen RN, Forristal CE, Barbier V, Nowlan B, Cisterne A, Bendall
LJ, Sims NA and Lévesque JP: Hematopoietic stem cell mobilizing
agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms
of action on bone marrow HSC niches and bone formation. Leukemia.
26:1594–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
